Pathways in Human Cancer

Complimentary Poster


Technical Support

Our scientists are at the bench daily to produce and validate our antibodies, so they have hands-on experience and knowledge of each antibody’s performance.

Contact a Scientist

"Understanding Signaling Pathways in Cancer", a symposium presented by the Koch Institute in partnership with Cell Signaling Technology, brought together speakers from leading cancer research organizations to present their latest findings on the signaling pathways leading to cancer.

Joan Brugge, Ph.D.

Joan Brugge, Ph.D., Harvard Medical School Matrix Dependent Rewiring of Signaling Pathways Following Targeted Therapies

Joan Brugge, Ph.D., Chair of the Department of Cell Biology at Harvard Medical School, discussed her work examining pathways that allow for drug resistance of extracellular matrix-attached tumors.

Michael J. Comb, Ph.D.

Michael J. Comb, Ph.D., Cell Signaling Technology Mapping Signaling Networks in Cancer: Phosphorylation and Beyond

Michael J. Comb, Ph.D., the founder, CEO, and Research Director of Cell Signaling Technology Inc., discussed his company’s achievements in antibody technologies that are being used to define signaling networks as a means to advance personalized medicine.

Rudolf Jaenisch, Ph.D.

Rudolf Jaenisch, Ph.D., Whitehead Institute Stem Cells, Pluripotency and Nuclear Reprogramming

Rudolf Jaenisch, Ph.D. of the Whitehead Institute discussed the stochastic and hierarchical events that occur at the single cell level during nuclear reprogramming.

William Kaelin, M.D.

William Kaelin, M.D., Dana-Farber Cancer Institute The VHL Tumor Suppressor Protein: Insights into Oxygen Sensing and Cancer Metabolism

William Kaelin, M.D., of the Dana Farber Cancer Institute, discussed the connections between altered metabolism and the transformation of some cancers.

Douglas Lauffenburger, Ph.D.

Douglas Lauffenburger, Ph.D., MIT Dept. of Biological Engineering Multi-Scale In Vivo Systems Analysis of Cell Signaling in Inflammatory Pathologies

Douglas Lauffenburger, Ph.D. from the MIT Department of Biological Engineering discussed a systems biology engineering approach for the creation of models that describe and predict the responses of in vivo signaling pathways.

Rune Linding, Ph.D.

Rune Linding, Ph.D., Technical University of Denmark Biological Forecasting and Modeling of Cancer Kinome Networks

Prof. Rune Linding, Ph.D. from the Technical University of Denmark (DTU) discussed his work developing biological forecasting and the analysis of cancer kinomes using algorithms to predict the behaviors of complex signaling networks.

Benjamin Neel, Ph.D., M.D.

Benjamin Neel, Ph.D., M.D., University Health Network A New Role For Gab Proteins In Control Of Cell Polarity

Benjamin Neel, Ph.D., M.D., Director of the Ontario Cancer Institute, discussed his work on the regulation of signaling networks controlling tight junction-mediated cell polarity.

David Sabatini, Ph.D., M.D.

David Sabatini, Ph.D., M.D., Whitehead Institute Growth By The mTOR Pathway

David Sabatini, Ph.D., M.D. of the Whitehead Institute at MIT discussed his work defining the role of mTOR in the amino acid sensing pathway.

Jeffrey Settleman, Ph.D.

Jeffrey Settleman, Ph.D., MGH Cancer Center, Harvard Medical School The Many Flavors of Resistance To Anti-Cancer Drugs

Jeffrey Settleman, Ph.D., the Senior Director of Discovery Oncology at Genentech, discussed his work investigating non-genetic/nonmutational drug-resistance to cancer therapeutics.

Forest M. White, Ph.D.

Forest M. White, Ph.D., Koch Institute at MIT Connecting Genetics To Phenotype Through Quantitative Proteomics

Forest M. White, Ph.D., Associate Professor of Biological Engineering of the Koch Institute at MIT discussed his work using quantitative proteomics to analyze the systemic effect of genetic mutation on phenotype.

Michael B. Yaffe, Ph.D., M.D.

Michael B. Yaffe, Ph.D., M.D., Koch Institute at MIT Harnessing Cross-Talk Between Signaling Pathways to Improve Cancer Treatment

Michael B. Yaffe, Ph.D., M.D., Professor of Biology and Biological Engineering at MIT, discussed his work examining the use of multiple anti-cancer therapeutics to dynamically re-wire signaling networks.